Anti-mag antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and iv cyclophosphamide

Gregory Blume, Alan Pestronk, L. T. Goodnough

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

Treatment outcomes of sensory-motor polyneuropathies associated with anti--myelin-associated glycoprotein (MAG) antibodies have varied even with relatively intensive immunosuppression. We used plasma exchange and cyclophosphamide to treat four patients with anti-MAG antibody-associated polyneuropathies whose symptoms had progressed in the preceding year. Treatment courses consisted of five to seven monthly regimens of plasma exchange on 2 consecutive days followed by intravenous cyclophosphamide (1 g/m2). Effects of treatment were quantitatively measured with hand-held dynamometry. All four patients showed improvement in both strength and sensation in the 5 to 24 months after treatment. We conclude that selected patients with sensory-motor polyneuropathies associated with high-titer serum IgM autoantibodies against MAG may have quantitative and useful functional improvement after immunotherapy. The improvement continues after completion of treatment and may persist for 1 to 2 years or longer.

Original languageEnglish
Pages (from-to)1577-1580
Number of pages4
JournalNeurology
Volume45
Issue number8
DOIs
StatePublished - Aug 1995

Fingerprint Dive into the research topics of 'Anti-mag antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and iv cyclophosphamide'. Together they form a unique fingerprint.

Cite this